Innovation Pharmaceuticals Inc (IPIX)

[frrol]

Buyout prices for pre-rev biotechs are based primarily on projected revenue multiples. A distant secondary consideration is previous stock price, and with a huge caveat: It is not the current stock price that matters but the "recent high". And if that high implies a buyout price that is financially unjustifiable, it is ignored. And keep in mind we have issued a lot of shares since our highs, which would make it even less justifiable.
That being said, our diluted market cap high was around $700MM, and that is high but not an outlandish price and would now come to over $3 per share. If P results are good, that could be doubled. If incredible, tripled. (Ignore the dumb pumping.)